Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
Rhea-AI Summary
Longeveron (NASDAQ: LGVN) will report 2025 full-year financial results and provide a business update on Tuesday, March 17, 2026 after U.S. markets close. The company will host a conference call and webcast the same day at 4:30 p.m. ET. An archived replay will be available on the company website under Events & Presentations.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – LGVN
On the day this news was published, LGVN declined 0.43%, reflecting a mild negative market reaction. Argus tracked a peak move of +41.6% during that session. Argus tracked a trough of -7.1% from its starting point during tracking. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $100K from the company's valuation, bringing the market cap to $23.25M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LGVN was down 8.81% with no peers in the momentum scanner. Broader biotech peers showed mixed single-day moves (some up, some down), suggesting LGVN’s move was more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Private placement funding | Positive | +68.3% | Announced private placement up to $30M to fund operations into 4Q2026. |
| Feb 25 | Phase 2b results | Positive | -5.6% | Reported Phase 2b data showing improved 6MWT in age-related frailty. |
| Feb 13 | CEO appointment | Positive | +3.0% | Appointed Stephen H. Willard as CEO with focus on Phase 2b HLHS data. |
| Feb 05 | Policy and trial update | Positive | -5.3% | Highlighted PRV program reauthorization and progress of 40‑patient HLHS trial. |
| Jan 29 | Patent grant | Positive | -2.4% | Announced Japan patent grant extending MSC potency assay IP to 2041. |
Positive operational and financing news has often met with mixed or negative price reactions, with only the recent financing and CEO appointment aligning positively with subsequent price moves.
Over the last few months, Longeveron has reported several catalysts: a private placement of up to $30 million on Mar 10, 2026, positive Phase 2b frailty data on Feb 25, 2026, a new CEO appointment on Feb 13, 2026, legislative support for rare pediatric disease incentives on Feb 5, 2026, and a Japanese potency-assay patent on Jan 29, 2026. Despite generally constructive news, price reactions have been inconsistent, so today’s earnings-date announcement fits into an already volatile backdrop.
Market Pulse Summary
This announcement schedules Longeveron’s 2025 full-year financial results for March 17, 2026 with a conference call at 4:30 p.m. ET. In recent months, the company has secured funding, advanced clinical programs, and expanded IP, while the stock showed mixed reactions to generally positive developments. Ahead of the call, investors may focus on cash runway, updates on the Phase 2b HLHS and frailty programs, and any guidance that builds on the recent financing and trial milestones.
AI-generated analysis. Not financial advice.
MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.
Conference Call and Webcast Details:
| Conference Call Number: | 1.877.407.0789 |
| Conference ID: | 13758462 |
| Call meTM Feature: | Click Here |
| Webcast: | Click Here |
An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (LOMECEL-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), Pediatric Dilated Cardiomyopathy (PDCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
